Explore 3 Stock Ideas & Industry Insights Download Free Report

AnaptysBio Inc

Company price
46.25 USD -1.52 ( 3.18%)
Last update at 2026-11-13T21:00:00Z
VOLUME
499637
Market Cap
2116.40M

Momentum Score

…

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company's products include Rosnilimab, a selective pathogenic T cell deplete which completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist, which is in a Phase 1b trial for celiac disease and eosinophilic esophagitis; ANB101, a BDCA2 modulator antibody which is in Phase 1a trial that specifically targets plasmacytoid dendritic cells and inhibits interferon secretion and modulates antigen presentation; dostarlimab, a PD-1 antagonist for various solid tumor indications; and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. It focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has collaborations agreement with GSK and Vanda. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
44.64
Low
47.36
High
52 Week Price Range
11.40
Low
54.83
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

AnaptysBio is a clinical-stage biotechnology company that develops therapeutic antibody product candidates using its proprietary antibody discovery platform, with programs focused on immunology, inflammatory diseases and oncology. Long-term growth may be driven by clinical trial progress, licensing or collaboration agreements and successful development or commercialization of lead candidates. Investors may find the company attractive for exposure to platform-based biologic innovation and potential upside if programs achieve regulatory approval.

Key risks include clinical and regulatory failure, ongoing financing needs given limited or no product revenue, and intense competition in antibody therapeutics.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
47.77
Dividend Yield
-
Revenue TTM
234.60M
Revenue Per Share
8.16
Gross Profit TTM
98.63M
Debt / Equity
0.38
ROE
-24.49%
Net Debt
-224.08M
ROCE
14.70%
Diluted EPS TTM
-0.46

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -13.07M -145.23M -163.62M -128.70M -57.80M
Net income -13.23M -145.23M -163.62M -128.72M -57.19M
Selling general administrative 50.74M 42.39M 41.95M 36.64M 21.49M
Gross profit 232.18M -72.56M -115.13M 10.29M 63.17M
Reconciled depreciation 2.42M 2.40M 2.38M 2.33M 2.09M
Ebit 47.90M -95.14M -157.07M -115.15M -56.81M
Ebitda 50.32M -92.74M -156.42M -107.59M -56.35M
Depreciation and amortization 2.42M 2.40M 0.65M 7.56M 0.47M
Non operating income net other - - - -18.37M -1.40M
Operating income 47.90M -114.95M -164.41M -115.15M -56.81M
Other operating expenses 186.71M 206.23M 181.57M 125.44M 119.99M
Interest expense 79.89M 50.09M 18.08M 21.11M 1.45M
Tax provision 0.16M 0.00M -0.00M 0.02M 0.00M
Interest income 13.50M 19.79M 17.83M 7.55M 0.43M
Net interest income -66.39M -30.29M 0.46M -13.56M -1.02M
Income tax expense 0.16M 0.00M -0.00M 0.02M -0.60M
Total revenue 234.60M 91.28M 17.16M 10.29M 63.17M
Total operating expenses 184.28M 42.39M 49.28M 125.44M 119.99M
Cost of revenue 2.42M 163.84M 132.28M - -
Total other income expense net -60.96M -30.28M 0.79M -13.55M -0.98M
Net income from continuing ops -13.23M -145.23M -147.82M -128.72M -57.80M
Net income applicable to common shares - - - -128.72M -57.80M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 364.39M 483.83M 452.39M 610.38M 643.07M
Other current assets 4.76M 5.74M 9.08M 4.54M 4.90M
Total liab 327.19M 412.97M 364.29M 348.28M 286.64M
Total stockholder equity 37.21M 70.87M 88.10M 262.10M 356.43M
Other current liab 32.67M 39.50M 30.97M 21.63M 12.85M
Common stock 0.03M 0.03M 0.03M 0.03M 0.03M
Capital stock 0.03M 0.03M 0.03M 0.03M 0.03M
Retained earnings -772.56M -759.33M -614.10M -450.48M -321.75M
Other liab - - - 304.41M 251.09M
Other assets - - - 0.26M 0.26M
Cash 238.20M 123.08M 35.97M 71.31M 495.73M
Total current liabilities 38.62M 45.43M 37.44M 26.05M 16.10M
Net debt -224.08M 246.38M -18.15M -51.86M -474.77M
Short term debt 2.08M 1.93M 1.78M 1.64M 1.50M
Short long term debt total 14.11M 369.46M 17.81M 19.45M 20.95M
Other stockholder equity 809.76M 829.86M 702.97M 717.80M 678.58M
Property plant equipment - - - 2.09M 2.28M
Total current assets 350.25M 431.88M 406.83M 447.20M 553.88M
Long term investments 0.00M 35.47M 27.03M 142.94M 67.10M
Net tangible assets - - - 584.33M 626.97M
Short term investments 73.44M 262.29M 354.94M 369.93M 52.37M
Net receivables 33.85M 40.77M 6.85M 1.42M 0.88M
Inventory - - 0.00M - -0.88M
Accounts payable 3.87M 4.00M 4.70M 2.78M 1.74M
Accumulated other comprehensive income -0.02M 0.30M -0.80M -5.25M -0.42M
Common stock total equity - - - 0.03M 0.03M
Retained earnings total equity - - - -450.48M -321.75M
Non currrent assets other 0.26M 0.26M 0.26M 0.26M 0.26M
Non current assets total 14.14M 51.96M 45.55M 163.18M 89.19M
Capital lease obligations 14.11M 16.04M 17.81M 19.45M 20.95M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 228.12M 95.40M 117.07M -394.49M 40.19M
Change to liabilities - - - 9.70M -4.74M
Total cashflows from investing activities 228.03M 95.40M 144.75M -394.85M 38.84M
Total cash from financing activities -132.61M 127.05M -59.30M 44.02M 252.30M
Change to operating activities - - - -2.32M -1.87M
Net income 49.61M -145.23M -163.62M -128.72M -57.80M
Change in cash 115.12M 87.11M -35.34M -424.42M 245.21M
Begin period cash flow 123.08M 35.97M 71.31M 495.73M 250.52M
End period cash flow 238.20M 123.08M 35.97M 71.31M 495.73M
Total cash from operating activities 19.70M -135.34M -120.80M -73.59M -45.92M
Issuance of capital stock 14.26M 100.84M 5.63M 11.83M 2.55M
Depreciation 2.42M 2.40M 2.38M 2.33M 2.09M
Other cashflows from investing activities - - - - 0.01M
Dividends paid - - 11.73M - -
Change to inventory - - 5.11M - -
Change to account receivables 6.92M -33.91M -5.43M -0.54M -0.88M
Sale purchase of stock -68.63M -0.46M -50.00M 11.83M 2.55M
Other cashflows from financing activities -1.45M -8.10M -0.04M 32.19M 249.75M
Change to netincome - - - 18.60M 1.94M
Capital expenditures 0.09M 0.36M 0.81M 0.36M 1.37M
Cash flows other operating - - - 26.16M 14.05M
Cash and cash equivalents changes - - - -424.42M 245.21M
Change in working capital -80.72M -66.33M -0.32M 6.84M -7.49M
Stock based compensation 36.07M 34.05M 33.20M 27.36M 15.35M
Other non cash items 12.31M 39.77M 7.56M 18.60M 1.45M
Free cash flow 19.61M -135.69M -121.61M -73.95M -47.29M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
ANAB
AnaptysBio Inc
-1.52
3.18%
46.25 - - 9.02 52.15 7.00 23.73
NVO
Novo Nordisk A/S
0.98
2.41%
41.63 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc
-4.02
0.74%
538.60 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc
4.28
0.45%
955.47 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE
64.70
7.19%
965.00 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

AnaptysBio Inc

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company's products include Rosnilimab, a selective pathogenic T cell deplete which completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist, which is in a Phase 1b trial for celiac disease and eosinophilic esophagitis; ANB101, a BDCA2 modulator antibody which is in Phase 1a trial that specifically targets plasmacytoid dendritic cells and inhibits interferon secretion and modulates antigen presentation; dostarlimab, a PD-1 antagonist for various solid tumor indications; and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. It focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has collaborations agreement with GSK and Vanda. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

10770 Wateridge Circle, San Diego, CA, United States, 92121-5801

858 362 6295

104

Name Title Year Born
Mr. Daniel R. Faga Interim Pres & CEO and Director 1980
Mr. Eric J. Loumeau COO & Gen. Counsel 1963
Mr. Hamza Suria M.B.A., M.Sc. Advisory 1976
Dr. Paul F. Lizzul FAAD, M.B.A., M.D., M.P.H., Ph.D. Chief Medical Officer 1975
Mr. Dennis M. Mulroy Chief Financial Officer 1955
Mr. Benjamin Stone Sr. VP of Corp. Devel. NA
Ms. Beth Mueller Sr. VP of HR NA
Dr. Martin Dahl Ph.D. Sr. VP of Research NA
Mr. Daniel R. Faga President, CEO & Director 1980
Mr. Eric J. Loumeau Chief Legal Officer 1963

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…